These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 10732743

  • 1. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E, Verweij J, van Oosterom AT, Uges DR, Spinelli R, Valota O, de Vries EG, Groen HJ.
    Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
    [Abstract] [Full Text] [Related]

  • 2. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
    Bakker M, Droz JP, Hanauske AR, Verweij J, van Oosterom AT, Groen HJ, Pacciarini MA, Domenigoni L, van Weissenbruch F, Pianezzola E, de Vries EG.
    Br J Cancer; 1998 Feb; 77(1):139-46. PubMed ID: 9459159
    [Abstract] [Full Text] [Related]

  • 3. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
    Cancer Chemother Pharmacol; 2007 Jan 15; 59(1):139-47. PubMed ID: 16819636
    [Abstract] [Full Text] [Related]

  • 5. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL, Tseng YL.
    Cancer; 2001 May 01; 91(9):1826-33. PubMed ID: 11335910
    [Abstract] [Full Text] [Related]

  • 6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson CE.
    Cancer Chemother Pharmacol; 2004 Dec 01; 54(6):514-24. PubMed ID: 15322827
    [Abstract] [Full Text] [Related]

  • 8. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH.
    Cancer Chemother Pharmacol; 2004 Sep 01; 54(3):241-8. PubMed ID: 15173955
    [Abstract] [Full Text] [Related]

  • 9. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
    Roh JK, Rha SY, Lee CI, Lee KH, Lee JJ, Shim HJ, Lee SD, Kim WB, Yang J, Kim SH, Lee MG.
    Int J Clin Pharmacol Ther; 1998 Jun 01; 36(6):312-9. PubMed ID: 9660038
    [Abstract] [Full Text] [Related]

  • 10. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R.
    Anticancer Res; 2000 Jun 01; 20(1B):485-91. PubMed ID: 10769710
    [Abstract] [Full Text] [Related]

  • 11. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
    Kotsakis A, Kouroussis Ch, Androulakis N, Agelaki S, Kalbakis K, Vamvakas L, Vardakis N, Kalykaki A, Polyzos A, Georgoulias V, Mavroudis D.
    Oncology; 2006 Jun 01; 71(3-4):190-6. PubMed ID: 17641537
    [Abstract] [Full Text] [Related]

  • 12. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP.
    Clin Cancer Res; 2004 May 15; 10(10):3386-95. PubMed ID: 15161693
    [Abstract] [Full Text] [Related]

  • 13. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
    Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK.
    Clin Cancer Res; 2006 Oct 01; 12(19):5755-63. PubMed ID: 17020981
    [Abstract] [Full Text] [Related]

  • 14. Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
    Alexandre J, Raymond E, Kaci MO, Brain EC, Lokiec F, Kahatt C, Faivre S, Yovine A, Goldwasser F, Smith SL, MacDonald JR, Misset JL, Cvitkovic E.
    Clin Cancer Res; 2004 May 15; 10(10):3377-85. PubMed ID: 15161692
    [Abstract] [Full Text] [Related]

  • 15. Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.
    de Jong RS, Mulder NH, Uges DR, Sleijfer DT, Höppener FJ, Groen HJ, Willemse PH, van der Graaf WT, de Vries EG.
    Br J Cancer; 1999 Feb 15; 79(5-6):882-7. PubMed ID: 10070885
    [Abstract] [Full Text] [Related]

  • 16. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y.
    Cancer Chemother Pharmacol; 2006 Aug 15; 58(2):173-82. PubMed ID: 16308697
    [Abstract] [Full Text] [Related]

  • 17. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
    Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, Huang KC, Kwiatkowski D, Skarin A, Eder JP.
    Clin Cancer Res; 2002 Mar 15; 8(3):691-7. PubMed ID: 11895897
    [Abstract] [Full Text] [Related]

  • 18. Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
    Unger C, Häring B, Medinger M, Drevs J, Steinbild S, Kratz F, Mross K.
    Clin Cancer Res; 2007 Aug 15; 13(16):4858-66. PubMed ID: 17699865
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
    Lyass O, Hubert A, Gabizon AA.
    Clin Cancer Res; 2001 Oct 15; 7(10):3040-6. PubMed ID: 11595693
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C, Dumez H, Calvert H, Hanauske A, Faber M, Wanders J, Yule M, Ravic M, Fumoleau P.
    Clin Cancer Res; 2003 Nov 01; 9(14):5195-204. PubMed ID: 14613999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.